Company Overview

SeaStar Medical Holding Corporation is a medical technology company focused on developing and commercializing immunomodulatory therapies for patients with life-threatening conditions characterized by excessive inflammation. The company operates within the medical device and biotechnology industries, with a primary emphasis on critical care, nephrology, and inflammatory diseases. Its core product development centers on the Selective Cytopheretic Device (SCD), an extracorporeal therapy designed to modulate the immune response rather than suppress it, targeting conditions such as acute kidney injury (AKI), sepsis, and cardiorenal syndromes.

The company’s primary revenue drivers to date are research and development activities, clinical trial progress, and regulatory milestones rather than commercial product sales. SeaStar Medical primarily serves hospital-based critical care settings and specialty care providers treating severely ill patients. Its strategic positioning is based on a novel mechanism of action that selectively targets activated immune cells, which differentiates it from traditional pharmaceutical immunosuppressive approaches. SeaStar Medical traces its origins to academic and clinical research into inflammation-mediated organ failure and later transitioned into a publicly traded entity to fund advanced clinical development and regulatory efforts.

Business Operations

SeaStar Medical’s operations are organized around a single core business focused on the development of the Selective Cytopheretic Device (SCD) platform. The company generates value through device development, clinical validation, regulatory submissions, and intellectual property management rather than diversified commercial operations. Its activities are largely concentrated in clinical research, manufacturing coordination, and regulatory engagement with U.S. authorities.

The company operates primarily in the United States, with clinical trials conducted at select domestic and international medical centers. SeaStar Medical controls proprietary device technology and related patents supporting the SCD platform. It operates through its wholly owned operating subsidiary, SeaStar Medical, Inc., which conducts substantially all research, development, and operational activities. Public disclosures do not indicate the presence of material joint ventures; however, the company collaborates with clinical research institutions and hospital systems as part of its development strategy.

Strategic Position & Investments

SeaStar Medical’s strategic direction is focused on advancing the SCD toward regulatory approval and eventual commercialization, beginning with pediatric AKI indications and expanding into broader critical care applications. Growth initiatives center on completing clinical trials, securing regulatory clearances, and scaling manufacturing capabilities in preparation for potential market entry. The company has also emphasized lifecycle expansion of the SCD technology into adult indications and other inflammatory-driven conditions.

Major investments have been directed toward clinical development, regulatory infrastructure, and intellectual property protection rather than acquisitions. Publicly available information does not indicate a diversified investment portfolio or multiple operating subsidiaries beyond SeaStar Medical, Inc. The company is positioned within emerging therapeutic approaches that blend medical devices with immunotherapy, an area of increasing interest within critical care medicine.

Geographic Footprint

SeaStar Medical is headquartered in the United States, with its principal executive offices and core operations located domestically. The company’s primary market focus is the U.S. healthcare system, particularly tertiary and quaternary care hospitals that manage critically ill patients. Regulatory engagement is largely centered on U.S. authorities, including submissions and interactions related to device approval pathways.

Internationally, SeaStar Medical has a limited but notable presence through clinical trial sites and research collaborations in select regions outside the U.S. These activities support data generation and potential future market expansion but do not currently represent large-scale commercial operations. Overall, the company’s geographic footprint remains concentrated in North America, with incremental international exposure tied to development rather than sales.

Leadership & Governance

SeaStar Medical is led by an executive team with experience in medical devices, healthcare commercialization, and public company governance. The leadership emphasizes disciplined clinical development, regulatory compliance, and a strategy focused on addressing unmet needs in critical care through innovative immunomodulatory technology. Governance is overseen by a board of directors with backgrounds in healthcare, finance, and medical innovation.

Key executives include:

• Eric Schlorff – Chief Executive Officer
• David Green – Chief Financial Officer
• Kevin Chung – Chief Operating Officer
• Dr. Robert Quinn – Chief Medical Officer

Information regarding the company’s original founder or founding leadership is data inconclusive based on available public sources, as disclosures emphasize current executive management rather than a single identifiable founder.